CNV1014802

DRUG4 trials

Sponsors

Biogen

Conditions

HealthyLumbosacral RadiculopathyTrigeminal Neuralgia

Phase 1

PK & Tolerability of CNV1014802 in Young and Elderly Healthy Volunteers

CompletedNCT02359344

BiogenTrigeminal Neuralgia

Start: 2015-02-03End: 2015-04-20Updated: 2017-10-12

Study to Evaluate the Interaction Between a Drug and CNV1014802 in Healthy Subjects

CompletedNCT02551497

Start: 2015-04-30End: 2016-08-26Updated: 2017-10-16

Phase 2

A Phase IIa Withdrawal Study of CNV1014802 in Patients With Trigeminal Neuralgia

CompletedNCT01540630

BiogenTrigeminal Neuralgia

Start: 2012-03-31End: 2014-06-30Updated: 2019-01-10

Crossover Study of CNV1014802 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy

CompletedNCT01561027

BiogenLumbosacral Radiculopathy

Start: 2011-04-30End: 2012-08-31Updated: 2017-10-13

Related Papers

Challenges recruiting to a proof-of-concept pharmaceutical trial for a rare disease: the trigeminal neuralgia experience.

2018-12-278 citations

Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial.

2017-02-17134 citations

Novel design for a phase IIa placebo-controlled, double-blind randomized withdrawal study to evaluate the safety and efficacy of CNV1014802 in patients with trigeminal neuralgia.

2013-11-2335 citations